

# FASTER, CHEAPER, BETTER WAYS TO END TUBERCULOSIS (TB)

## WE STRIVE TO:



Quickly identify at-risk people with **better diagnostics**



Protect people at high risk with **preventive treatment**



**Cut prices of vital new drugs** and put them in reach of all



Create **shorter, more effective, less expensive treatments** for multidrug-resistant TB



Encourage diagnostic and drug manufacturers **to innovate and compete**


## UNITAID SUPPORTS THE END TB GOALS



reduction in the number of **TB deaths by 2035**



reduction in **TB incidence rate by 2035**



TB affected families **facing catastrophic costs due to TB by 2035**

## TB KILLS THREE PEOPLE EVERY MINUTE




**10.4<sup>M</sup>**

**new TB cases worldwide** in 2015, including 1.2 million people living with HIV, and 1 million children



**1.8<sup>M</sup>**

**people died from TB** in 2015, of whom 0.4 million were co-infected with HIV



**580,000**

**people fell ill** with drug-resistant TB in 2015



**AREA**



**PROJECT**



**GRANTEE**



**BUDGET**



**TIMELINE**

**TB  
CROSS-CUTTING**

US \$  
**102.4M**

Quality assurance of TB medicines	WHO	US\$ 33.7 m	2006 – 2016
Quality assurance of TB diagnostics	WHO	US\$ 10.5 m	2009 – 2016
Preventing patent barriers to TB medicines	Medicines Patent Pool	US\$ 29.2 m	2016 – 2020

**TB  
DIAGNOSTICS**

US \$  
**115.5M**

Rolling out innovative TB and MDR-TB diagnostics (Xpert)	WHO, Stop TB Partnership	US\$ 25.9 m	2013 – 2016
Expanding MDR-TB diagnostics	WHO, Stop TB Partnership, Foundation for Innovative New Diagnostics (FIND)	US\$ 89.6 m	2009 – 2016

**TB  
TREATMENT**

US \$  
**171.1M**

New child-friendly and fixed-dose combinations for children suffering from TB	TB Alliance, WHO	US\$ 16.7 m	2013 – 2016
Introducing new second-line medicines to manage MDR-TB	Partners in Health, Médecins Sans Frontières, Interactive Research and Development	US\$ 60.4 m	2015 – 2019
Access to first-line TB medicines to minimize risk of stock-outs	Stop TB Partnership	US\$ 27.6 m	2007 – 2011
Access to second-line TB medicines	Stop TB Partnership	US\$ 53.3 m	2007 – 2013
Access to TB medicines for children	Stop TB Partnership	US\$ 13.14 m	2007 – 2013
Access to quality-assured and affordable MDR-TB treatment through a rotating stockpile	Stop TB Partnership	US\$ 29 m	2008 – 2016

**Upcoming Tuberculosis interventions:**

<b>CROSS-CUTTING</b>	Policy and technical support	WHO	tbc	under development
<b>PREVENTION</b>	Enabling preventive TB treatment in high-risk groups	Grant to be confirmed	tbc	under development
<b>TREATMENT</b>	Scale up better TB treatment in children	Grant to be confirmed	tbc	under development
<b>TREATMENT</b>	Speed access to shorter MDR-TB treatment	Call to be launched	tbc	under development

UNITAID supports several interventions to improve prevention, diagnosis, treatment and care of HIV-associated TB.